Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PANRETIN vs AKLIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.
AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.
FDA-approved: Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi sarcoma,Off-label: Treatment of chronic hand eczema (oral formulation, not available in US)
FDA-approved for the topical treatment of acne vulgaris in patients 9 years of age and older
Apply 0.1% gel topically to lesions twice daily.
Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.
Mean terminal half-life of approximately 5-10 hours; clinical context: supports twice-daily topical application.
Terminal elimination half-life: ~29 hours after topical application; supports once-daily dosing.
Metabolized primarily by CYP2C9, CYP3A4, and CYP2C8 to major metabolites (e.g., 4-oxo-alitretinoin, 9-cis-retinoic acid). Glucuronidation also contributes.
Trifarotene is metabolized primarily via CYP2D6 and to a lesser extent via CYP3A4. It undergoes extensive first-pass metabolism with low systemic exposure after topical application.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine.
Fecal: ~70% as unchanged drug; Renal: <1% as metabolites.
>99% bound to plasma proteins, primarily albumin and lipoproteins.
>99% bound to plasma proteins (primarily albumin and lipoproteins).
Not applicable for topical administration; systemic absorption is minimal with no established Vd.
Not determined for topical route; systemic absorption minimal with Vd not clinically relevant.
Systemic bioavailability after topical application is <1% of applied dose.
Topical: ~1% systemic absorption; oral: not applicable.
No dose adjustment required for renal impairment.
No dose adjustment required in renal impairment. Not studied in severe renal impairment.
No dose adjustment recommended for hepatic impairment.
No dose adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C).
Not indicated for pediatric patients below 18 years of age.
Approved for acne vulgaris in patients aged 12 years and older: apply a thin layer to affected areas once daily in the evening.
No specific dose adjustment; use with caution due to potential for increased skin sensitivity.
No specific dose adjustment required; clinical studies did not include sufficient geriatric patients to determine differential response.
Not applicable for topical formulation. Oral alitretinoin (not marketed in US) carries a boxed warning for teratogenicity and must not be used during pregnancy.
None.
Teratogenicity: Avoid use during pregnancy; effective contraception required,Photosensitivity: Avoid excessive sun exposure,Local skin reactions: erythema, edema, peeling at application site,Hyperlipidemia: Monitor lipids in prolonged use,Pancreatitis: Risk in patients with hypertriglyceridemia,Hepatotoxicity: Monitor liver function tests,Pseudotumor cerebri: Discontinue if signs of intracranial hypertension
Local skin reactions (erythema, scaling, dryness, stinging/burning) may occur; reduce frequency or discontinue if severe.,Avoid excessive exposure to sunlight or UV light; use sunscreens and protective clothing.,Avoid contact with eyes, mouth, angles of the nose, and mucous membranes.,Pregnancy: Limited data; no known risk of major malformations based on animal studies, but use only if clearly needed.
Hypersensitivity to alitretinoin or any component of the formulation,Pregnancy (topical: use only if no safer alternative; oral: absolutely contraindicated)
Hypersensitivity to trifarotene or any component of the formulation
No known food interactions. Avoid concurrent use of other topical products on the same area.
No significant food interactions reported. Avoid excessive alcohol consumption as it may exacerbate skin dryness and irritation. No specific dietary restrictions.
PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnormalities). First trimester exposure carries highest risk. Second and third trimester: risk of fetal retinoid syndrome (craniofacial dysmorphism, CNS anomalies, cardiovascular malformations). Effective contraception must be used.
Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters: Limited data; avoid unless benefit outweighs risk.
No data on excretion in human milk. Retinoids are known to be excreted in animal milk. Because of potential for serious adverse reactions in nursing infants (teratogenicity, retinoid toxicity), breastfeeding is contraindicated during therapy and for at least 1 month after last dose.
No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for serious adverse reactions in nursing infants.
Contraindicated in pregnancy; no dose adjustments applicable. Ensure patient is not pregnant before initiating therapy.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy unknown. Use lowest effective dose if necessary.
Panretin (alitretinoin) gel is a topical retinoid indicated for cutaneous Kaposi sarcoma. Use gloves during application; avoid application to normal skin as it may cause irritation. Monitor for local adverse reactions like erythema, edema, and pain. Do not use concurrently with other topical agents on the same site.
AKLIEF (trifarotene) is a fourth-generation retinoid selective for RAR-γ receptors, minimizing irritation compared to tretinoin. Use pea-sized amount for entire face; avoid excessive application. Initiate every other night to improve tolerability. Concomitant use of benzoyl peroxide or salicylic acid may increase dryness; advise non-comedogenic moisturizers. Contraindicated in pregnancy (Category X); rule out pregnancy before starting.
Apply a thin layer only to Kaposi sarcoma lesions, avoiding healthy skin.,Wash hands thoroughly before and after application.,Do not cover with bandages or dressings unless instructed.,Expected side effects include redness, swelling, and pain at application site.,Avoid exposure to sunlight or tanning lamps; use sunscreen on treated areas.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Apply a thin layer once daily at night to clean, dry skin.,Avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily.,May cause initial redness, peeling, and dryness; use moisturizer.,Do not use if pregnant or planning pregnancy; use effective contraception.,Do not apply to cuts, abrasions, or eczematous skin.,Avoid waxing or laser hair removal during treatment.,Therapeutic effect may take 8-12 weeks.,Keep out of reach of children and away from eyes, mouth, and mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PANRETIN vs AKLIEF, answered by our medical review team.
PANRETIN is a Topical Retinoid that works by Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.. AKLIEF is a Topical Retinoid that works by AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PANRETIN and AKLIEF depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PANRETIN is: Apply 0.1% gel topically to lesions twice daily.. The standard adult dose of AKLIEF is: Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PANRETIN and AKLIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PANRETIN is classified as Category C. PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnor. AKLIEF is classified as Category C. Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.